Vasoactive Intestinal Peptide (VIP) Research

VIP is a 28-amino-acid peptide belonging to the secretin and glucagon superfamily, which also includes secretin, glucagon, the glucagon-like peptides, and PACAP (pituitary adenylate cyclase-activating polypeptide). It was originally described in 1970 as a peripheral and splanchnic vasodilator, and its biology was mapped progressively over the following decades.

VIP signals through two class B G protein-coupled receptors, VPAC1 and VPAC2. Both respond to VIP and to the closely related PACAP with high affinity, and both generally raise intracellular cyclic AMP when activated. A third related receptor, PAC1, is selective for PACAP. VPAC1 is broadly expressed across the central nervous system and peripheral tissues including lung, liver, and intestine, while VPAC2 has a distribution that includes immune tissue and the master circadian clock [1].

The signature feature of VIP is how many systems it touches. In research models it has been described across the following contexts:

One of the most studied dimensions of VIP is its role as an immunomodulator. Across preclinical work it has been characterized as an anti-inflammatory mediator that can dampen activation of macrophages and dendritic cells and shift responses toward regulatory and Th2 patterns. It has been examined in a range of inflammatory and autoimmune research models, and this body of work is the basis for describing VIP as a pleiotropic immune signaling molecule rather than a simple gut hormone [2].

An important caveat runs through this literature: the great majority of the immune findings come from cell and animal models. They describe mechanisms and research signals, not established outcomes in people.

A distinctive and well-supported role for VIP lies in timekeeping. The suprachiasmatic nucleus of the hypothalamus, a small paired structure of roughly 20,000 neurons, functions as the central circadian clock in mammals. VIP and its receptor VPAC2 are concentrated in this circuit, where they help synchronize individual cellular oscillators into a single coherent rhythm. Research using intersectional genetics and live imaging has identified the VIP to VPAC2 axis as a pacemaking hub that sets the period and phase of the whole network, which is why VIP is often described as essential to robust circadian function [3].

Because VIP and its receptors belong to the same secretin and glucagon superfamily as the incretins, there is research interest in its metabolic signaling. Work in this area has examined VPAC2 in the context of insulin secretion and glucose handling, positioning VIP and VPAC2 as a potential research target within type 2 diabetes models [4]. This remains an investigational research direction rather than an established application.

The synthetic form of VIP, known as aviptadil, has been carried into human trials, most prominently for acute respiratory failure. This is where an honest reading of the evidence matters, because the clinical record is more sobering than many summaries imply.

An early randomized, placebo-controlled trial in patients with critical COVID-19 respiratory failure did not meet its primary endpoint, although it reported a signal toward improved survival at day 60 in a secondary analysis [5]. That signal drew considerable attention. It was then tested in a much larger, definitive randomized trial, TESICO, part of the NIH ACTIV program. In that trial intravenous aviptadil did not improve the primary recovery endpoint, did not improve mortality, and did not improve any other measured endpoint compared with placebo [6]. Aviptadil is not an approved therapy, and research-grade VIP is unapproved material for research use only.

VIP is a compelling research subject precisely because it sits at the intersection of so many systems, gut, lung, immune, and brain, all through a compact 28-amino-acid sequence and a shared VPAC receptor system. The strongest and most reproducible research signals are in receptor pharmacology, immune modulation, and circadian biology. The clinical picture is narrower and, in its largest test to date, negative. VIP also has a very short circulating half-life, which is itself a significant constraint on how it can be studied. Holding both the breadth of the preclinical work and the limits of the clinical record at once is the accurate way to understand where VIP research stands.

VIP research overlaps with several gut, immune, and neurological peptide topics covered in our research library:

KPV Peptide: Anti-Inflammatory Research · Thymosin Alpha-1: Immune Modulation Research · Semax and Selank: Neurological Research

Preclinical and clinical literature has examined this neuropeptide and its research context across several interconnected themes:

What Is Vasoactive Intestinal Peptide (VIP)?

VIP is a 28-amino-acid peptide belonging to the secretin and glucagon superfamily, which also includes secretin, glucagon, the glucagon-like peptides, and PACAP (pituitary adenylate cyclase-activating polypeptide). It was originally described in 1970 as a peripheral and splanchnic vasodilator, and its biology was mapped progressively over the following decades.

VIP signals through two class B G protein-coupled receptors, VPAC1 and VPAC2. Both respond to VIP and to the closely related PACAP with high affinity, and both generally raise intracellular cyclic AMP when activated. A third related receptor, PAC1, is selective for PACAP. VPAC1 is broadly expressed across the central nervous system and peripheral tissues including lung, liver, and intestine, while VPAC2 has a distribution that includes immune tissue and the master circadian clock [1].

Where VIP Acts: A Broad Distribution

The signature feature of VIP is how many systems it touches. In research models it has been described across the following contexts:

VIP in Immune Research

One of the most studied dimensions of VIP is its role as an immunomodulator. Across preclinical work it has been characterized as an anti-inflammatory mediator that can dampen activation of macrophages and dendritic cells and shift responses toward regulatory and Th2 patterns. It has been examined in a range of inflammatory and autoimmune research models, and this body of work is the basis for describing VIP as a pleiotropic immune signaling molecule rather than a simple gut hormone [2].

An important caveat runs through this literature: the great majority of the immune findings come from cell and animal models. They describe mechanisms and research signals, not established outcomes in people.

VIP and the Circadian Clock

A distinctive and well-supported role for VIP lies in timekeeping. The suprachiasmatic nucleus of the hypothalamus, a small paired structure of roughly 20,000 neurons, functions as the central circadian clock in mammals. VIP and its receptor VPAC2 are concentrated in this circuit, where they help synchronize individual cellular oscillators into a single coherent rhythm. Research using intersectional genetics and live imaging has identified the VIP to VPAC2 axis as a pacemaking hub that sets the period and phase of the whole network, which is why VIP is often described as essential to robust circadian function [3].

VIP in Metabolic Research

Because VIP and its receptors belong to the same secretin and glucagon superfamily as the incretins, there is research interest in its metabolic signaling. Work in this area has examined VPAC2 in the context of insulin secretion and glucose handling, positioning VIP and VPAC2 as a potential research target within type 2 diabetes models [4]. This remains an investigational research direction rather than an established application.

Clinical Investigation: The Aviptadil Evidence Picture

The synthetic form of VIP, known as aviptadil, has been carried into human trials, most prominently for acute respiratory failure. This is where an honest reading of the evidence matters, because the clinical record is more sobering than many summaries imply.

An early randomized, placebo-controlled trial in patients with critical COVID-19 respiratory failure did not meet its primary endpoint, although it reported a signal toward improved survival at day 60 in a secondary analysis [5]. That signal drew considerable attention. It was then tested in a much larger, definitive randomized trial, TESICO, part of the NIH ACTIV program. In that trial intravenous aviptadil did not improve the primary recovery endpoint, did not improve mortality, and did not improve any other measured endpoint compared with placebo [6]. Aviptadil is not an approved therapy, and research-grade VIP is unapproved material for research use only.

Interpreting the Vasoactive Intestinal Peptide Research Landscape

VIP is a compelling research subject precisely because it sits at the intersection of so many systems, gut, lung, immune, and brain, all through a compact 28-amino-acid sequence and a shared VPAC receptor system. The strongest and most reproducible research signals are in receptor pharmacology, immune modulation, and circadian biology. The clinical picture is narrower and, in its largest test to date, negative. VIP also has a very short circulating half-life, which is itself a significant constraint on how it can be studied. Holding both the breadth of the preclinical work and the limits of the clinical record at once is the accurate way to understand where vasoactive intestinal peptide research stands.

Related Research Reading

VIP research overlaps with several gut, immune, and neurological peptide topics covered in our research library:

KPV Peptide: Anti-Inflammatory Research · Thymosin Alpha-1: Immune Modulation Research · Semax and Selank: Neurological Research

Research Pathways Associated with VIP

Preclinical and clinical literature has examined this neuropeptide and its research context across several interconnected themes: